EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57

Abstract

THE CLINICAL OUTCOME OF IVABRADINE AND NEBIVOLOL IN THE TREATMENT OF STABLE ANGINA PECTORIS PATIENTS WITH MILD LEFT VENTRICULAR DYSFUNCTION

Dr. Mohammad Rashedul Hasan* and Dr. Mahmudul Hasan

ABSTRACT

Background: In chronic stable angina, increased heart rate contributes to the development of symptoms and signs of myocardial ischaemia by increasing myocardial oxygen demand and reducing diastolic perfusion time. Objective: In this study our main goal is to evaluate the clinical outcome of Ivabradine and Nebivolol in the Treatment of Stable Angina Pectoris Patients with Mild Left Ventricular Dysfunction. Methods: This cross-sectional observational study was done at Noakhali 250-Bed General Hospital from April 2020 to December 2020. A total of 200 consecutive patients were included. The patients were evaluated in 2 different groups (1,2). In group-1 Nebivolol 5mg/day was administered to the 100 patients included in Group A. 100 patients were started on Ivabradine 10mg/day and these patients were included into group-2. Result: During the study, according to systolic Diastolic BP and heart rate heart rate decreased (79±7) to (66±5.1) in Group: 1 and (78± 7) to (71 ± 5) in Group: 2. After 6 months’ treatment LVEF for the group-1 improved by (45 ± 6.5) to (52 ± 3.1), and for the group-2 (48± 5.5) to (53 ± 2.1). There is no significant change in EF improvement in both groups. Also, dose-related sinus bradycardia occurred in (5%) of the nebivolol-using patients included in Group-1, where as in group-2 it was 1%. Conclusion: In patients with tachycardia caused angina, Ivabradine can be treated as the first alternative, as this heart rate reducer and chest pain agent. Nebivolol should be treated with the hypertensive tachycardia patient. Better findings are required for further analysis.

Keywords: Coronary heart disease (CHD), Ivabradine, Nebivolol.


[Full Text Article] [Download Certificate]

Citation

  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44

INDEXING

NEWS & UPDATION

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 March 2024 Issue has been Published, Kindly check it on https://www.ejpmr.com/issue

  • EJPMR: MARCH ISSUE PUBLISHED

    MARCH 2024 issue has been successfully launched on MARCH 2024.

  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia